| This is the quarterly release of non-diabetic hyperglycaemia data collected from GP practices alongside the National Diabetes Audit (NDA)
This is the quarterly release of data from the National Diabetes Audit
Dapagliflozin decreased the incidence of reported episodes of AF/AFL adverse events in high-risk patients with T2DM. This effect was consistent regardless of the patients’ prior history of AF, ASCVD, or HF (circulation)
Technology appraisal guidance [TA622] (NICE)
In DKD patients the galectin-3 and GDF-15 levels were inversely related to the eGFR which was further confirmed by the ROC curve demonstrating the potential of galectin-3 and GDF-15 as a biomarker (Diabetes Research and Clinical Practice)
SGLT2 inhibitors had glucose-lowering effects comparable to those of DPP4 inhibitors but more favorable pleiotropic effects on body weight, ALT and eGFR changes, potentially improving type 2 diabetes patients’ cardio-metabolic disease risks (Cardiovascular Diabetology)
While confirmatory of the exploratory data from CVOTs, CREDENCE provides the first robust data on the effects of canagliflozin on patient relevant renal endpoints. Extrapolation to a conclusion of a SGLT2 inhibitor class effect cannot be made until additional renal trials with other SGLT2 inhibitors are reported (Diabetes, Obesity and Metabolism)
| 
